Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) and CymaBay Therapeutics (NASDAQ: CBAY)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) and CymaBay Therapeutics (NASDAQ: CBAY) with bullish sentiments.

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), with a price target of $2.50. The company’s shares closed yesterday at $1.46, close to its 52-week high of $1.48.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -8.0% and a 36.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and Synergy Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $3.83.

CymaBay Therapeutics (NASDAQ: CBAY)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on CymaBay Therapeutics (NASDAQ: CBAY), with a price target of $21. The company’s shares closed yesterday at $13.09.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 21.2% and a 42.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Conatus Pharmaceuticals.

Currently, the analyst consensus on CymaBay Therapeutics is Strong Buy and the average price target is $19.57, representing a 49.5% upside.

In a report issued on April 4, Cantor Fitzgerald also maintained a Buy rating on the stock with a $16 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.